JoshuaDavidSchiffmanMD
Pediatric Hematology & Oncology • Salt Lake City, UTCancer Genetics/Cancer Risk Assessment, Pediatric Sarcoma Oncology
CEO & Co-Founder, Peel Therapeutics, Inc.
Dr. Schiffman is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
100 N Mario Capecchi Dr
Salt Lake City, UT 84113Phone+1 801-662-4700Fax+1 801-662-4705- Is this information wrong?
Summary
- Dr. Joshua Schiffman is a pediatric hematologist/oncologist in Salt Lake City, UT and is affiliated with multiple hospitals in the area, including Primary Children's Hospital and University of Utah Health. He received his medical degree from The Warren Alpert Medical School of Brown University and has been in practice 17 years. He specializes in cancer genetics/cancer risk assessment and pediatric sarcoma oncology. Most recently, Dr. Schiffman is the CEO and Co-Founder of Peel Therapeutics, an evolution-driven biotech company.
Education & Training
Stanford Health Care-Sponsored Stanford UniversityFellowship, Pediatric Hematology/Oncology, 2004 - 2007- Stanford Health Care-Sponsored Stanford UniversityResidency, Pediatrics, 2000 - 2004
The Warren Alpert Medical School of Brown UniversityClass of 2000
Certifications & Licensure
CA State Medical License 2001 - Present
UT State Medical License 2008 - 2026- American Board of Pediatrics Pediatrics
- American Board of Pediatrics Pediatric Hematology-Oncology
Clinical Trials
- Biomarker in Tissue Samples From Patients With Ewing Sarcoma Start of enrollment: 2011 May 01
- Neutrophil Extracellular Trap Formation in Patients Undergoing Bone Marrow Transplant Start of enrollment: 2012 Jun 01
- Genetic Biomarkers in Saliva Samples From Patients With Ewing Sarcoma Start of enrollment: 2012 Dec 01
- Join now to see all
Publications & Presentations
PubMed
- 1 citationsTP53 germline pathogenic variant frequency in anaplastic rhabdomyosarcoma: A Children's Oncology Group report.Douglas Fair, Luke Maese, Yueh-Yun Chi, Minjie Li, Douglas S Hawkins, Rajkumar Venkatramani, Erin Rudzinski, David Parham, Lisa Teot, David Malkin, Sharon E Plon, He L...> ;Pediatric Blood & Cancer. 2023 May 17
- 12 citationsNETosis induction reflects COVID-19 severity and long COVID: insights from a 2-center patient cohort study in Israel.Nitzan Krinsky, Sofia Sizikov, Sivan Nissim, Adi Dror, Anna Sas, Hodaya Prinz, Ester Pri-Or, Shay Perek, Ayelet Raz-Pasteur, Izabella Lejbkowicz, Sivan Ida Cohen-Matsl...> ;Journal of Thrombosis and Haemostasis. 2023 Sep 1
- 1 citationsElephant TP53-RETROGENE 9 induces transcription-independent apoptosis at the mitochondria.Aidan J Preston, Aaron Rogers, Miranda Sharp, Gareth Mitchell, Cristhian Toruno, Brayden B Barney, Lauren N Donovan, Journey Bly, Ryan Kennington, Emily Payne, Anthony...> ;Cell Death Discovery. 2023 Feb 16
- Join now to see all
Press Mentions
- Huntsman Cancer Institute March Research HighlightsApril 5th, 2023
PEEL Therapeutics Announces Possible New Treatment for COVID-19June 29th, 2020
Researchers Find Elephant Protein That May Help in the War on CancerJanuary 19th, 2017- Join now to see all
Hospital Affiliations
Primary Children's HospitalSalt Lake City, Utah
University of Utah HealthSalt Lake City, Utah
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
